IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort

Sevindik, Omur Gokmen; Mersin, Sinan; Katgi, Abdullah; Tunali, Sunay; Solmaz, Şerife; Acar, Celal; Alacacıoğlu, İnci; Pişkin, Özden; Özcan, Mehmet Ali; Demırkan, Fatih; Ündar, Bülent; Özsan, Güner Hayri

doi:10.1016/j.clml.2015.02.004

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations support the inclusion of these two risk factors for the purposes of developing risk stratification models and the lower importance, in this regard, of advanced age and CV risk factors. However, multiple other studies have identified CV risk factors and advanced age as independent risk factors for thrombosis in ET and the issue needs additional studies using different age limits and CV risk profiles to hopefully reconcile the observed discrepancies. Regardless, a notation for the presence of CV risk factors in specific risk categories is therapeutically relevant from the standpoint of the need for aspirin therapy, once or twice daily .…”

Section: Discussionmentioning

confidence: 96%

Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients

et al. 2016

View full text Add to dashboard Cite

The primary objective of treatment in essential thrombocythemia (ET) is to prevent thromboembolic complications. In this regard, advanced age and thrombosis history have long distinguished “low” from “high” risk patients. More recently, JAK2V617F and cardiovascular (CV) risk factors were identified as additional modifiers, leading to the development of a 3‐tiered International Prognostic Score of Thrombosis for ET (IPSET‐thrombosis): “low,” “intermediate,” and “high”. The international data set used to develop IPSET‐thrombosis was recently re‐analyzed in order to quantify the additional pro‐thrombotic effect of JAK2V617F and CV risk factors in specific risk subcategories. The revised IPSET‐thrombosis identified four risk categories based on three adverse variables (thrombosis history, age >60 years and JAK2V617F): very low (no adverse features), low (presence of JAK2V617F), intermediate (age >60 years) and high (presence of thrombosis history or presence of both advanced age and JAK2V617F). In this study of 585 patients with ET (median age 68 years; 61% female), we validated the revised IPSET‐thrombosis by confirming significant differences in thrombosis risk between “very low” and “low” (HR 2.4, 95% CI 1.1 − 5.3) and between “intermediate” and “high” (HR 2.3, 95% CI 1.1 − 5.2) risk patients. Furthermore, in multivariable analysis, only JAK2V617F (HR=1.8, CI= 1.07 − 2.94) and history of thrombosis (HR=2.1, CI= 1.20 − 3.58) were independently predictive of future thrombotic events. The revised IPSET‐thrombosis needs confirmation in prospective studies, especially in terms of risk‐adapted therapy that includes the need for aspirin therapy in very low risk, twice‐daily aspirin therapy for low risk and cytoreductive therapy for low or intermediate risk patients. Am. J. Hematol. 91:390–394, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 96%

Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Furthermore, one or more thrombotic episodes occurred in 5.4% of low-risk, 26.7% of intermediate-risk, and 66.2% of high-risk groups. 36 The estimated median survival of PMF is 6 years, but it can be a few months to years. In clinical practice, IPSS is used at diagnosis to predict survival in patients with PMF.…”

Section: Dovepressmentioning

confidence: 99%

Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital

Sukrisman¹

2022

JBM

View full text Add to dashboard Cite

Background: Philadelphia-negative myeloproliferative neoplasms (Ph-MPNs) are clonal hematopoietic cell malignancy that comprises polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). They prone to develop thrombosis, bleeding, fibrotic progression, and leukemic transformation. We aimed to study clinical characteristics, thrombosis complications, and prognostic risk in Indonesians with Ph-MPNs. Methods: This was a single-center retrospective cross-sectional study, including patients with Ph-MPNs who attended Hematology and Medical Oncology outpatient clinic at Cipto Mangunkusumo General Hospital, Jakarta, between 2016 and 2021. Demographic data, clinical characteristics, previous antiplatelet treatment, baseline laboratory data, JAK2V617F mutation, and treatment were reviewed for analysis. The prognostic risk model was assessed for PV (IPSS), ET (IPSET-thrombosis), and PMF (IPSS and DIPPS) patients.Results: One hundred forty-six patients were classified as PV (31.5%), ET (38.4%), and PMF (30.1%) with median ages of 54, 53.5, and 55 years, respectively. PMF presented with the most diverse clinical presentations. JAK2V617 mutations were detected in 82%, 42.5%, and 76.5% of PV, ET, and PMF patients. PV had the highest thrombosis event pre/at diagnosis (26.1%), with predominantly arterial thrombosis. Bleeding occurred more in PMF (20.5%). Phlebotomy and hydroxyurea are the only treatment available for Ph-MPNs in the government hospital in Indonesia. IPSS intermediate risk in PV (47.8%), IPSET-thrombosis low risk in ET (46.4%), were the most common risk groups. Conclusion: Essential thrombocythemia was the most prevalent Ph-MPNs in Indonesia. Arterial thrombosis was the highest thrombosis event pre/at diagnosis in PV despite IPSET-thrombosis low risk being the most common risk group. In JAK2V617 mutation-positive MPN population, thrombosis event was also the highest in PV.

show abstract

Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions

2022

View full text Add to dashboard Cite

IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort

Cited by 5 publications

References 20 publications

Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients

Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET‐thrombosis) in 585 Mayo clinic patients

Clinical Characteristics and Prognostic Risks of Philadelphia-Negative Myeloproliferative Neoplasms at Cipto Mangunkusumo General Hospital

Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions

Contact Info

Product

Resources

About